



(11) **EP 1 203 025 B1**

(12) **EUROPEAN PATENT SPECIFICATION**

(45) Date of publication and mention of the grant of the patent:  
**01.07.2009 Bulletin 2009/27**

(21) Application number: **00950330.1**

(22) Date of filing: **13.07.2000**

(51) Int Cl.:  
**A61K 39/395** (2006.01) **A61K 38/00** (2006.01)  
**A61K 31/00** (2006.01) **A61K 31/7088** (2006.01)  
**C07K 14/705** (2006.01) **A61K 47/48** (2006.01)  
**A61K 51/00** (2006.01) **G01N 33/53** (2006.01)  
**A61P 9/00** (2006.01) **A61P 17/06** (2006.01)  
**A61P 25/00** (2006.01) **A61P 35/00** (2006.01)  
**A61P 35/04** (2006.01)

(86) International application number:  
**PCT/US2000/019095**

(87) International publication number:  
**WO 2001/004157 (18.01.2001 Gazette 2001/03)**

(54) **NOVEL METHOD AND COMPOSITION FOR INHIBITION OF ANGIOGENESIS USING ANTAGONISTS BASED ON MMP-9 AND BETA1 INTEGRINS**

METHODE UND ZUSAMMENSETZUNG ZUR ANGIOGENESE-INHIBIERUNG MIT ANTAGONISTEN GEGEN MMP-9 UND BETA1-INTEGRINE

NOUVELLES METHODE ET COMPOSITION D'INHIBITION DE L'ANGIOGENESE UTILISANT DES ANTAGONISTES BASES SUR LES INTEGRINES MMP-9 ET BETA1

(84) Designated Contracting States:  
**AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE**  
Designated Extension States:  
**AL LT LV MK RO SI**

(30) Priority: **13.07.1999 US 143581 P**  
**02.09.1999 US 152495 P**

(43) Date of publication of application:  
**08.05.2002 Bulletin 2002/19**

(73) Proprietor: **UNIVERSITY OF SOUTHERN CALIFORNIA**  
**Los Angeles, CA 90007-4344 (US)**

(72) Inventors:  
• **BROOKS, Peter, C.**  
**Hollywood, CA 90028 (US)**  
• **HASSANIEH, Loubna**  
**Agoura Hills, CA 91301 (US)**  
• **RODRIGUEZ, Dorothy**  
**West Harrison, New York 10604 (US)**

(74) Representative: **Fiener, Josef**  
**Patentanw. J. Fiener et col.,**  
**P.O. Box 12 49**  
**87712 Mindelheim (DE)**

(56) References cited:  
**WO-A-95/14714** **WO-A-99/58139**

- **VARNER J A ET AL: "ANTAGONISTS OF VASCULAR CELL INTEGRIN ALPHA5BETA1 INHIBIT ANGIOGENESIS" CIRCULATION, US, AMERICAN HEART ASSOCIATION, DALLAS, TX, vol. 98, no. 17, November 1998 (1998-11), page 4166 XP000857372 ISSN: 0009-7322**
- **KOIVUNEN E ET AL: "Tumor targeting with a selective gelatinase inhibitor." NATURE BIOTECHNOLOGY, (1999 AUG) 17 (8) 768-74. , XP000941541**
- **LOZONSCHI L ET AL: "Controlling tumor angiogenesis and metastasis of C26 murine colon adenocarcinoma by a new matrix metalloproteinase inhibitor, KB-R7785, in two tumor models." CANCER RESEARCH, (1999 MAR 15) 59 (6) 1252-8. , XP000941536**
- **BROOKS P C: "Role of integrins in angiogenesis." EUROPEAN JOURNAL OF CANCER, (1996 DEC) 32A (14) 2423-9. REF: 67 , XP000941543**

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

**EP 1 203 025 B1**

- **BROOKS, PETER C. (1): "MMP-9 binds to a ligand induced cryptic site within b1 integrin: Role in angiogenesis and tumor growth." IN VITRO CELLULAR & DEVELOPMENTAL BIOLOGY ANIMAL, (MARCH, 2000) VOL. 36, NO. 3 PART 2, PP. 29.A. PRINT. MEETING INFO.: MEETING OF THE SOCIETY FOR IN VITRO BIOLOGY WORLD CONGRESS ON IN VITRO BIOLOGY SAN DIEGO, CALIFORNIA, USA JUNE 10-15, 2000 , XP000943742**

**Description****FIELD OF THE INTENTION**

5 **[0001]** The invention relates generally to the field of medicine, and relates specifically to methods and compositions for inhibiting angiogenesis in a tissue or detecting angiogenesis using antagonists of specified sequences found within MMP-9 and/or  $\beta 1$  integrins.

**BACKGROUND**

10 **[0002]** Tumor growth and metastasis impacts a large number of people each year. In fact, it is estimated that well over 600,000 new cases of cancer will be diagnosed in the coming year in the United States alone (Varner, J. A., Brooks, P. C., and Cheresh, D. A. (1995) *Cell Adh. Commun.* 3, 367-374). Numerous studies have suggested that the growth of all solid tumors requires new blood vessel growth for continued expansion of the tumors beyond a minimal size (Varner *et al.* 1995; Blood, C. H. and Zetter, B. R. (1990) *Biochim. Biophys. Acta.* 1032:89-118; Weidner, N. *et al.* (1992) *J. Natl. Cancer Inst.* 84:1875-1887; Weidner, N. *et al.* (1991). *N. Engl. J. Med.* 324:1-7; Brooks, P. C. *et al.* (1995) *J. Clin. Invest.* 96:1815-1822; Brooks, P. C. *et al.* (1994) *Cell* 79:1157-1164; Brooks, P. C. *et al.* (1996). *Cell* 85, 683-693; Brooks, P. C. *et al.* (1998) *Cell* 92:391-400.

20 **[0003]** *Circulation*, 98(17), 1998, p. 4166 teaches that expression of integrin  $\alpha 5\beta 1$  is upregulated on the blood vessels in human tumours. Integrin  $\alpha 5\beta 1$  colocalizes with vascular cell expression of fibronectin. Inhibitors of  $\alpha 5\beta 1$  inhibit tumour induced angiogenesis and tumour growth in a mouse model. As inhibitors serve antibodies, peptides and organic molecules.

**[0004]** WO-A-95/14714 relates to  $\alpha 5\beta 1$  integrin-binding peptides which are used in a therapeutic method for inhibiting metastasis of tumour cells (see pages 3-4, example VII, claims 64-69).

25 **[0005]** *Nature Biotechnology*, vol. 17, August 1999, 768-774 discloses cyclic peptide inhibitors of MMP-9 (see abstract). Peptid CTTHWGFTLC is used in a method of delaying breast carcinoma formation and increasing the survival of tumour-bearing animals (see p. 770, right column, fifth paragraph and p. 771, right column, last paragraph).

30 **[0006]** *Cancer Research*, March 1999, 59(5), 1252-1258 discloses the hydroxamic acid-based MMP-9 inhibitor KB-R7785. Intraperitoneal administration twice daily results in 88.2% suppression of tumour growth in a mouse tumour model (see abstract). KB-R7785 interferes with early steps of angiogenesis (see p. 1257).

35 **[0007]** WO-A-99/58139 (falling within the terms of Art. 54(3) EPC) discloses a method of inhibiting angiogenesis by contacting the tissue of interest with an  $\alpha 5\beta 1$  integrin antagonist. The antagonist is an anti- $\alpha 5\beta 1$  integrin antibody, a peptide comprising sequence CRRETAWAC or a nonpeptide organic molecule. It also describes and claims screening assays for the detection of further  $\alpha 5\beta 1$  integrin antagonists as well as therapeutical and diagnostic applications of the antagonists of interest.

**[0008]** A wide variety of other human diseases also are characterized by unregulated blood vessel development, including ocular diseases such as macular degeneration and diabetic retinopathy. In addition, numerous inflammatory diseases also are associated with uncontrolled neovascularization such as arthritis and psoriasis (Varner *et al.* 1995).

40 **[0009]** New blood vessels develop from pre-existing vessels by a physiological process known as angiogenesis (Varner *et al.* 1995; Blood and Zetter 1990; Weidner *et al.* 1992). This complex process requires cooperation of a variety of molecules including growth factors, cell adhesion receptors, matrix degrading enzymes and extracellular matrix components (Varner *et al.* 1995; Blood and Zetter 1990; Weidner *et al.* 1992). Thus, therapies designed to block angiogenesis may affect the growth of solid tumors. In fact, clear evidence has been provided that blocking tumor neovascularization can inhibit tumor growth in various animal models, and human clinical data is beginning to support this contention as well (Varner, J. A., Brooks, P. C., and Cheresh, D. A. (1995) *Cell Adh. Commun.* 3,367-374).

45 **[0010]** It has also been proposed that inhibition of angiogenesis can be effected by (1) inhibition of release of "angiogenic molecules" such as  $\beta$ FGF (fibroblast growth factor), (2) neutralization of angiogenic molecules, such as by use of anti- $\beta$ FGF antibodies, and (3) inhibition of endothelial cell response to angiogenic stimuli. This latter strategy has received attention, and Folkman *et al.*, *Cancer Biology*, 3:89-96 (1992), have described several endothelial cell response inhibitors, including collagenase inhibitors, basement membrane turnover inhibitors, angiostatic steroids, fungal-derived angiogenesis inhibitors, platelet factor 4, thrombospondin, arthritis drugs such as D-penicillamine and gold thiomalate, vitamin D<sub>3</sub> analogs, alpha-interferon, and the like that might be used to inhibit angiogenesis. For additional proposed inhibitors of angiogenesis, see Blood and Zetter 1990; Moses *et al.* (1990) *Science* 248:1408-1410; Ingber *et al.* (1988) *Lab. Invest.*, 59:44-51; and U.S. Pat. Nos. 5,092,885, 5,112,946, 5,192,744, and 5,202,352.

55 **[0011]** To block angiogenesis, many investigators have also focused on growth factors and cytokines that initiate angiogenesis (Varner *et al.* 1995; Blood and Zetter 1990; Weidner *et al.* 1992; Weidner *et al.* 1991; Brooks *et al.* 1995; Brooks *et al.* 1994; Brooks *et al.* 1997). However, there is a large number of distinct growth factors and cytokines which have the capacity to stimulate angiogenesis. The therapeutic benefit of blocking a single cytokine may have only limited

benefit due to this redundancy. Accordingly, what is needed is other anti-angiogenic targets for inhibiting angiogenesis and proteolysis.

## SUMMARY

**[0012]** Invasive cells utilize the protein-protein interaction involving enzymes and integrin receptors to localize proteolytic activity to the cell surface and to promote invasive cell behavior. The present invention contemplates inhibiting angiogenesis and tumor growth using antagonists that target cell adhesion and proteolysis of the extracellular matrix (ECM). Specifically, the present invention contemplates inhibiting angiogenesis based on the discovery of a unique mechanism by which invasive cells localize proteolytic activity, which contributes to the cell surface.

**[0013]** An aspect of this invention provides uses of an antagonist for the manufacture of a medicament for inhibiting angiogenesis comprising antagonists that modify protein protein interactions involving certain sequences sequences found within the proteolytic enzyme MMP-9 and/or  $\beta 1$  integrin receptors. Such antagonists may include, but are not limited to, an antibody or functional fragment thereof, that immunoreacts with MMP-9 and the  $\beta 1$  integrin receptor.

**[0014]** Yet another aspect of the invention contemplates inhibiting angiogenesis comprising contacting a tissue with antagonists of cell adhesion and proteolysis of the extracellular matrix (ECM), such as, but not limited to an antibody or functional fragment thereof, that immunoreacts with MMP-9 and the  $\beta 1$  integrin receptor.

**[0015]** Another aspect of the invention contemplates inhibiting a disease state or angiogenesis in a tissue by for example, administering to the tissue a composition comprising an angiogenesis-inhibiting amount of an antagonist of the localization of the proteolytic enzyme MMP-9 to the cell surface. The disease state to which the invention is applied can be tumor growth or metastasis, macular degeneration, psoriasis, restenosis in a tissue, etc.

**[0016]** The tissue to be treated can be any tissue in which inhibition of angiogenesis is desirable, such as diseased tissue where neo-vascularization is occurring. Exemplary tissues include inflamed tissue, solid tumors, metastases, tissues undergoing restenosis, and the like.

**[0017]** Uses of an antagonist for the manufacture of a medicament for detecting angiogenesis, tumorous tissue, metastases, and tumor invasion into a tissue by contacting an antagonist of the invention with a tissue, are also provided.

**[0018]** The invention also provides methods for screening antagonists of the invention.

## BRIEF DESCRIPTION OF THE FIGURES

### [0019]

**FIGURE 1:** Shows the results of the purification of the  $\beta 1$  integrin,  $\alpha 5\beta 1$ , from placental lysates utilizing the 110kD cell binding domain of fibronectin.

**FIGURE 2:** Show the results of zymographic analysis of the  $\beta 1$  integrin,  $\alpha 5\beta 1$ , when purified  $\alpha 5\beta 1$  and  $\alpha v\beta 1$  are separated on 10% SDS PAGE gels co-polymerized with gelatin.

**FIGURE 3:** Shows the results of Western Blot Analysis of the  $\beta 1$  integrin,  $\alpha 5\beta 1$ , when purified integrins  $\alpha 5\beta 1$  and  $\alpha v\beta 1$  (1 $\mu$ g) are separated.

**FIGURE 4:** Shows the results of binding assay for recombinant MMP-9 binding to the  $\beta 1$  integrin,  $\alpha 5\beta 1$ , or control protein  $\beta$ -casein.

**FIGURE 5:** Shows the results of experiments in which recombinant MMP-9 is incubated with  $\alpha 5\beta 1$  positive and negative cells.

**FIGURE 6:** Shows the results of experiments to determine the co-localization of MMP-9 and, the  $\beta 1$  integrin,  $\alpha 5\beta 1$ , in human melanoma tumor blood vessels.

**FIGURE 7:** Shows the results of experiments to identify synthetic peptides that bind to MMP-9. FRIP-1 is SEQUENCE ID NO:1 and AAA is the AAA peptide, which is SEQUENCE ID NO:2.

**FIGURE 8A/8B:** Show the results of experiments in which the FRIP-1 peptide was injected into chick embryos in which angiogenesis had been induced.

**FIGURE 9:** Shows the results of experiments to generate Mabs directed to the synthetic peptide, FRIP-1 (SEQUENCE ID NO:1).

**FIGURE 10:** Shows the results of experiments in which recombinant human MMP-9 (2 $\mu$ g/ml) was allowed to bind in the presence or absence of Mabs FM155 or LM609.

**FIGURE 11:** Shows the results of experiments to determine the effects of systemic administration of FM155 on melanoma tumor growth.

## DETAILED DESCRIPTION OF THE INVENTION

**[0020]** In accordance with the present invention, it has been discovered that protein-protein interactions involving

certain sequences within the proteolytic enzyme MMP-9 and/or  $\beta 1$  integrin receptors contribute to angiogenesis and/or tumor growth by localizing the proteolytic activity to the cell surface. Thus, modifying such protein-protein interactions involving certain sequences found within the MMP-9 and/or  $\beta 1$  integrin receptors can inhibit angiogenesis and/or tumor growth.

5

#### THE INTERACTION BETWEEN MMP-9 AND $\beta 1$ INTEGRIN MMP-9

**[0021]** In the physiological state, the synthesis of connective tissues is in dynamic equilibrium with the degradation of the extracellular matrix. That degradation is due, in part, to matrix metalloproteases ("MMPs"), a family of proteases (enzymes) involved in the degradation and remodeling of connective tissues. Members of this family of endopeptidase enzymes are secreted as proenzymes from various cell types that reside in or are associated with connective tissue, such as fibroblasts, monocytes, macrophages, endothelial cells, and invasive or metastatic tumor cells. MMP expression is stimulated by growth factors and cytokines in the local tissue environment, where these enzymes act to specifically degrade protein components of the extracellular matrix, such as collagen, proteoglycans (protein core), fibronectin and laminin. These ubiquitous extracellular matrix components are present in the linings of joints, interstitial connective tissues, basement membranes and cartilage. The MMPs share a number of properties, including zinc and calcium dependence, secretion as zymogens, and 40-50% amino acid sequence homology.

10

15

**[0022]** Excessive degradation of extracellular matrix by MMPs is implicated in the pathogenesis of many diseases of both chronic and acute nature. For example, numerous studies, as reviewed in Exp. Opin. Invest. Drugs, 5, 323-335, (1996), have established that expression and activation of MMPs are critical events in tumor growth, invasion and metastasis. In addition, MMP activity has been found to be required for angiogenesis, which is necessary for tumor growth as well as for other pathological conditions such as macular degeneration.

20

**[0023]** The members of this family of enzymes includes, but is not limited to, collagenases (MMP-1), gelatinases or collagenases of type IV (MMP-2, MMP-9), matrilysin (MMP-7, PUMP-1), and stromelysins (MMP-3).

25

**[0024]** Of particular interest here, the gelatinase MMP-9 is a 92-kD enzyme released by mononuclear phagocytes, neutrophils, corneal epithelial cells, tumor cells, cytotrophoblasts and keratinocytes.

**[0025]** Many physiological processes require that cells come into close contact with other cells and/or extracellular matrix. Such adhesion events may be required for cell activation, migration, proliferation and differentiation. Cell-cell and cell-matrix interactions are mediated through several families of cell adhesion molecules (Cams) including the selectins, integrins, cadherins and immunoglobulins. Cams play an essential role in both normal and pathophysiological processes. Therefore, the targeting of specific and relevant Cams in certain disease conditions without interfering with normal cellular functions is essential for an effective and safe therapeutic agent that inhibits cell-cell and cell-matrix interactions.

30

**[0026]** Of the various Cams discussed above, the integrin superfamily is found in various combinations on nearly every mammalian cell type. (for reviews see: E. C. Butcher, Cell, 67, 1033 (1991); T. A. Springer, Cell, 76, 301 (1994); D. Cox et al., "The Pharmacology of the Integrins." Medicinal Research Rev. 14, 195 (1994) and V. W. Engleman et al., "Cell Adhesion Integrins as Pharmaceutical Targets." in Ann. Repts. in Medicinal Chemistry, Vol. 31, J. A. Bristol, Ed.; Acad. Press, NY, 1996, p. 191).

35

**[0027]** The integrins represent one of the best characterized superfamilies of adhesion receptors. Integrins are glycoprotein heterodimers which contain a non-covalently associated .alpha. ( $\alpha$ ) and .beta. ( $\beta$ ) subunit. Integrin subunits are transmembrane proteins which contain an extracellular domain for interacting with an extracellular matrix or cellular component, a transmembrane domain spanning the cell membrane and a cytoplasmic domain for interacting with one or more cytoskeletal components.

40

**[0028]** There are fourteen known  $\alpha$  subunits and eight known .beta. subunits which can pair to form at least twenty different integrin molecules. Several distinct integrin  $\alpha$  chains are capable of pairing with one type of .beta. chain to form a .beta. chain subfamily.

45

**[0029]** Of particular interest here is the .beta..sub.1 ( $\beta 1$ ) subfamily, which includes seven members (also known as the VLA proteins:  $\alpha 1\beta 1$  -  $\alpha 7\beta 1$ ). As the examples below show, angiogenesis and disease states can be inhibited using antagonists for modifying the protein-protein interactions involving certain amino acid sequences of the  $\beta 1$  integrins,  $\alpha 5\beta 1$  integrin being an example of such integrins. Throughout this specifications the terms  $\beta 1$  integrins and  $\beta 1$  containing integrins are used interchangeably.

50

#### ANTAGONISTS OF THE INVENTION

**[0030]** The examples provided herein establish that MMP-9 binds directly with the  $\beta 1$  integrin,  $\alpha 5\beta 1$  integrin. Thus, cells lacking the gene for making  $\beta 1$  integrins have a considerably reduced capacity for binding MMP-9. The examples also suggest that MMP-9 and  $\alpha 5\beta 1$  integrin may co-localize on the surface of a cell and blood vessels because they indicate that MMP-9 and  $\alpha 5\beta 1$  integrin are closely associated within both the human vascular compartment as well as

55

on the tumor cells themselves.

**[0031]** Further, an analysis of the amino acid sequences of MMP-9 and  $\alpha 5\beta 1$  integrin leads to a polypeptide identified as FRIP-1 (SEQUENCE ID NO: 1) for mediating the interaction between these two proteins. FRIP-1 binds to MMP-9 but a control peptide AAAA (SEQUENCE ID NO: 3) binds with substantially reduced affinity to MMP-9. FRIP-1 was found to inhibit angiogenesis.

**[0032]** Moreover, as the examples show, FRIP-1 can be used to identify antagonists for modifying the protein-protein interactions involving certain amino acid sequences within MMP-9 and/or  $\alpha 5\beta 1$  integrin. Thus, Mab FM155 was identified by injecting mice with FRIP-1 conjugated to a carrier protein. Mab FM155 was found to have a high specificity for FRIP-1 but did not react with the control peptide AAAA: SEQUENCE ID NO: 3.

**[0033]** The examples illustrate that Mab FM155 can potently inhibit tumor growth *in vivo*. Thus, Mab FM155 modifies the protein-protein interactions involving certain amino acid sequences within MMP-9 and/or  $\alpha 5\beta 1$  integrin.

**[0034]** Antagonists of the invention may be any type of molecule, including, but not limited to, peptides, polypeptides, non-peptidic molecules, for example, organic molecules and oligonucleotides, proteins, enzymes, antibodies, monoclonal and polyclonal, etc.

**[0035]** Antagonists of the invention bind to FRIP-1 but bind to the control peptide AAAA with substantially reduced affinity. Apparent affinities can be determined by methods such as an enzyme linked immunosorbent assay (ELISA) or any other technique familiar to one of skill in the art. True affinities can be measured by techniques known to one of skill in the art.

**[0036]** Further, as would be known to one of ordinary skill in the art, other antagonists directed specifically to the epitope defined by Mab FM155 can have similar anti-angiogenic and anti-tumor activities. Such antagonists include additional function blocking Mabs, humanized Mabs, chimeric Mabs, toxin conjugated Mabs, polyclonal antibodies, small peptide antagonists directed to this epitope, as well as organic and non-peptidic mimetics of the epitope defined by FM155. In addition, the epitopes defined by the monoclonal antibody FM155 may themselves function as potent anti-angiogenic and/or anti-tumor compounds. Moreover, peptides containing epitopes recognized by an antagonist can be used themselves. Thus, the invention can take on several embodiments.

**[0037]** For example, one embodiment of the invention is an antagonist that specifically modifies protein-protein interactions, wherein the protein-protein interactions comprise interactions between at least one amino acid sequence within a first protein and at least one amino acid sequence within a second protein. The first protein of such an antagonist can be MMP-9 or it can be a  $\beta 1$ -containing integrin. Alternatively, the first protein can be MMP-9 and the second protein can be a  $\beta 1$ -containing integrin. Further, in such a case, the protein-protein interactions may be such as to cause MMP-9 to bind to the  $\beta 1$ -containing integrin.

**[0038]** Alternatively, when the first protein is a  $\beta 1$ -containing integrin it can be  $\alpha 5\beta 1$  integrin or when the second protein is a  $\beta 1$ -containing integrin it can be  $\alpha 5\beta 1$  integrin

**[0039]** In one embodiment, the antagonist is such that the protein-protein interaction causes the co-localization of the first protein and the second protein on a cell surface or a blood vessel.

**[0040]** An antagonist of the invention is an antagonist that inhibits angiogenesis, tumor growth, or metastasis. In the general case, it can be an antagonist that inhibits a disease. Examples of such diseases are psoriasis, macular degeneration, a neurological disease, and restenosis in a tissue.

**[0041]** In another embodiment the antagonist of the invention is a monoclonal antibody. For example, it can be Mab FM155, it can be a monoclonal antibody having the binding specificity for at least one target of monoclonal antibody FM155, a humanized or chemically modified monoclonal antibody, or a fragment of a monoclonal antibody. Alternatively it could be a polyclonal antibody.

**[0042]** In one embodiment, the antagonist of the invention is conjugated to cytotoxic or cytostatic agents.

**[0043]** In another embodiment, the invention is an antagonist that specifically binds with SEQUENCE ID NO: 1 but binds to SEQUENCE ID NO: 3 with substantially reduced affinity. Such an antagonist inhibits angiogenesis and tumor growth. In this embodiment, the antagonist is a polypeptide, for example, a protein, or it is a polypeptide the amino acid sequence of which comprises SEQUENCE ID NO: 1. The polypeptide may be a monoclonal antibody, for example, FM 155.

## ANTIBODY ANTAGONISTS

**[0044]** The present invention contemplates antagonists in the form of antibodies, which, in the general case, modify protein-protein interactions involving certain amino acid sequences within MMP-9 and/or  $\beta 1$  integrin. Such antibodies could include antibodies that bind to a peptide with a polypeptide sequence, SEQUENCE ID NO: 1: but do not bind to a control peptide sequence of SEQUENCE ID NO: 3: Such antibody antagonists also can inhibit angiogenesis.

**[0045]** Antibodies of the invention can be monoclonal or polyclonal. In one embodiment, antibodies used are monoclonal. A monoclonal antibody of this invention comprises antibody molecules that immunoreact with MMP-9 and  $\alpha 5\beta 1$  integrin.

[0046] Preferred monoclonal antibodies which preferentially bind to FRIP-1 include monoclonal antibodies referred to as FM155.

[0047] Antibody antagonists of the invention can be generated according to a number of methods known to one of skill in the art. For example, an animal can be immunized with FRIP-1 or fragment thereof. Antibodies thus generated can be selected both for their ability to bind to FRIP-1 (SEQUENCE ID NO: 1:) but not to bind to control SEQUENCE ID NO: 3.

[0048] The term "antibody or antibody molecule" in the various grammatical forms is used herein as a collective noun that refers to a population of immunoglobulin molecules and/or immunologically active portions of immunoglobulin molecules, i.e., molecules that contain an antibody combining site or paratope.

[0049] An "antibody combining site" is that structural portion of an antibody molecule comprised of heavy and light chain variable and hypervariable regions that specifically binds antigen.

[0050] Exemplary antibodies for use in the present invention are intact immunoglobulin molecules, substantially intact immunoglobulin molecules and those portions of an immunoglobulin molecule that contain the paratope, including those portions known in the art as Fab, Fab', F(ab')<sub>2</sub> and F(v), and also referred to as antibody fragments.

[0051] In another preferred embodiment, the invention contemplates a truncated immunoglobulin molecule comprising a Fab fragment derived from a monoclonal antibody of this invention. The Fab fragment, lacking Fc receptor, is soluble, and affords therapeutic advantages in serum half life, and diagnostic advantages in modes of using the soluble Fab fragment. The preparation of a soluble Fab fragment is generally known in the immunological arts and can be accomplished by a variety of methods.

[0052] For example, Fab and F(ab')<sub>2</sub> portions (fragments) of antibodies are prepared by the proteolytic reaction of papain and pepsin, respectively, on substantially intact antibodies by methods that are well known. See for example, U.S. Pat. No. 4,342,566 to Theofilopolous and Dixon. Fab' antibody portions also are well known and are produced from F(ab')<sub>2</sub> portions followed by reduction of the disulfide bonds linking the two heavy chain portions as with mercaptoethanol, and followed by alkylation of the resulting protein mercaptan with a reagent such as iodoacetamide. An antibody containing intact immunoglobulin molecules are preferred, and are utilized as illustrative herein.

[0053] The phrase "monoclonal antibody" in its various grammatical forms refers to a population of antibody molecules that contain only one species of antibody combining site capable of immunoreacting with a particular epitope. A monoclonal antibody may therefore contain an antibody molecule having a plurality of antibody combining sites, each immunospecific for a different epitope, e.g., a bispecific monoclonal antibody.

[0054] A monoclonal antibody is typically composed of antibodies produced by clones of a single cell called a hybridoma that secretes (produces) only one kind of antibody molecule. The hybridoma cell is formed by fusing an antibody-producing cell and a myeloma or other self-perpetuating cell line. The preparation of such antibodies was first described by Kohler and Milstein, Nature 256:495-497 (1975). Additional methods are described by Zola, Monoclonal Antibodies: A Manual of Techniques, CRC Press, Inc. (1987). The hybridoma supernatants so prepared can be screened for the presence of antibody molecules that immunoreact with MMP-9 and/or  $\alpha 5\beta 1$  integrin.

[0055] Briefly, to form the hybridoma from which the monoclonal antibody composition is produced, a myeloma or other self-perpetuating cell line is fused with lymphocytes obtained from the spleen of a mammal hyperimmunized with FRIP-1.

[0056] It is preferred that the myeloma cell line used to prepare a hybridoma be from the same species as the lymphocytes. Typically, a mouse of the strain 129 GIX.sup.+ is the preferred mammal. Suitable mouse myelomas for use in the present invention include the hypoxanthine-aminopterin-thymidine-sensitive (HAT) cell lines P3X63-Ag8.653, and Sp2/0-Ag14 that are available from the American Type Culture Collection, Rockville, Md., under the designations CRL 1580 and CRL 1581, respectively.

[0057] Splenocytes are typically fused with myeloma cells using polyethylene glycol (PEG) 1500. Fused hybrids are selected by their sensitivity to a selective growth medium, such as HAT (hypoxanthine aminopterin thymidine) medium. Hybridomas producing a monoclonal antibody of this invention are identified using the enzyme linked immunosorbent assay (ELISA) described in the Examples.

[0058] A monoclonal antibody of the present invention also can be produced by initiating a monoclonal hybridoma culture comprising a nutrient medium containing a hybridoma that secretes antibody molecules of the appropriate specificity. The culture is maintained under conditions and for a time period sufficient for the hybridoma to secrete the antibody molecules into the medium. The antibody-containing medium is then collected. The antibody molecules can then be further isolated by well known techniques.

[0059] Media useful for the preparation of these compositions are both well known in the art and commercially available and include synthetic culture media, inbred mice and the like. An exemplary synthetic medium is Dulbecco's minimal essential medium (DMEM; Dulbecco et al., Virol. 8:396, 1959) supplemented with 4.5 g/L glucose, 20 nM glutamine, and 20% fetal calf serum. An exemplary inbred mouse strain is the Balb/c.

[0060] Other methods of producing a monoclonal antibody, a hybridoma cell, or a hybridoma cell culture also are well known. See, for example, the method of isolating monoclonal antibodies from an immunological repertoire as described

by Sastry et al. (1989) Proc. Natl. Acad. Sci. USA, 86:5728-5732; and Huse et al. (1989) Science, 246:1275-1281.

[0061] Also contemplated is the hybridoma cell, and cultures containing hybridoma cells that produce monoclonal antibodies of this invention. Particularly preferred is a hybridoma cell line that secretes monoclonal antibody FM155.

[0062] A monoclonal antibody that has the immunoreaction characteristics of FM155 is also contemplated.

[0063] One of skill in the art will know how to determine if a monoclonal antibody has an equivalent specificity (immunoreaction characteristics) as a monoclonal antibody of this invention by ascertaining whether the former prevents the latter from binding to a preselected target molecule. If the monoclonal antibody being tested competes with the monoclonal antibody of the invention, as shown by a decrease in binding by the monoclonal antibody of the invention in standard competition assays for binding to the target molecule when present in the solid phase, then it is likely that the two monoclonal antibodies bind to the same, or a closely related, epitope.

[0064] An additional way to determine whether a monoclonal antibody has the specificity of a monoclonal antibody of the invention is to determine the amino acid residue sequence of the CDR regions of the antibodies in question. Antibody molecules having identical, or functionally equivalent, amino acid residue sequences in their CDR regions have the same binding specificity. Methods for sequencing polypeptides are well known in the art. This does not suggest that antibodies with distinct CDR regions cannot bind to the same epitope.

[0065] The immunospecificity of an antibody, its target molecule binding capacity, and the attendant affinity the antibody exhibits for the epitope, are defined by the epitope with which the antibody immunoreacts. The epitope specificity is defined at least in part by the amino acid residue sequence of the variable region of the heavy chain of the immunoglobulin the antibody, and in part by the light chain variable region amino acid residue sequence.

[0066] Use of the term "having the binding specificity of" indicates that equivalent monoclonal antibodies compete for binding to a preselected target epitope.

[0067] Humanized monoclonal antibodies offer particular advantages over murine monoclonal antibodies, particularly insofar as they can be used therapeutically in humans. Specifically, human antibodies are not cleared from the circulation as rapidly as "foreign" antigens, and do not activate the immune system in the same manner as foreign antigens and foreign antibodies. Methods of preparing "humanized" antibodies are generally well known in the art, and can readily be applied to the antibodies of the present invention.

[0068] Thus, the invention contemplates, in one embodiment, a monoclonal antibody of this invention that is humanized by grafting to introduce components of the human immune system without substantially interfering with the ability of the antibody to bind antigen.

[0069] The antibody of the invention can also be a fully human antibody such as those generated, for example, by selection from an antibody phage display library displaying human single chain or double chain antibodies such as those described in de Haard, H.J. et al. (1999) J. Biol. Chem. 274:18218-30 and in Winter, G. et al. (1994) Annu. Rev. Immunol. 12:433-55.

## PEPTIDE/POLYPEPTIDE ANTAGONISTS

[0070] Antagonists of the invention method also can be polypeptides or peptides. The term polypeptide refers to a sequence of 3 or more amino acids connected to one another by peptide bonds between the alpha-amino group and carboxy group of contiguous amino acid residues, and includes within its meaning the class of compounds known as proteins. The term peptide as used herein refers to a linear series of two or more connected to one to the other as in a polypeptide.

[0071] In one embodiment, the invention method contemplates antagonists in the form of polypeptides. A polypeptide antagonist of the localization of MMP-9 to the cell surface can be any peptide or polypeptide capable of disrupting the localization of MMP-9 to the cell surface or, more generally, of modifying protein-protein interactions involving certain amino acid sequences within MMP-9 and/or  $\beta$ 1 integrin.

[0072] The identification of preferred antagonist peptides having selectivity for MMP-9 or  $\beta$ 1 integrins can readily be identified in a typical inhibition of binding assay, such as the ELISA assay described in the Examples.

[0073] Peptide and polypeptide antagonists can be generated by a number of techniques known to one of skill in the art. For example, a two hybrid system (*e.g.*, Fields, S. (1989) Nature 340:245-6) can use a fragment of MMP-9 as "bait" for selecting protein antagonists from a library that bind to the FRIP-1. The library of potential antagonists can be derived from a cDNA library, for example. In another embodiment, the potential antagonists can be variants of known MMP-9 binding proteins. Such proteins can be randomly mutagenized or subjected to gene shuffling, or other available techniques for generating sequence diversity.

[0074] Peptide and polypeptide antagonists of the invention method also can be generated by techniques of molecular evolution. Libraries of proteins can be generated by mutagenesis, gene shuffling or other available techniques for generating molecular diversity. Protein pools representing numerous variants can be selected for their ability to bind to FRIP-1, for instance by passing such protein pools over a solid matrix to which a FRIP-1 has been attached. Elution with gradients of salt, for example, can provide purification of variants with affinity for the FRIP-1. A negative selection

step also can be included whereby such pools are passed over a solid matrix to which the control peptide AAAA (SEQUENCE ID NO: 3) has been attached. The filtrate will contain those variants within the pool that have a reduced affinity for the AAAA.

**[0075]** Peptide and polypeptide antagonists of the invention method also can be generated by phage display. A randomized peptide or protein can be expressed on the surface of a phagemid particle as a fusion with a phage coat protein. Techniques of monovalent phage display are widely available (see, *e.g.*, Lowman H.B. et al. (1991) *Biochemistry* 30:10832-8.) Phage expressing randomized peptide or protein libraries can be panned with a solid matrix to which a AAAA molecule has been attached. Remaining phage do not bind AAAA, or bind AAAA with substantially reduced affinity. The phage are then panned against a solid matrix to which a FRIP-1 has been attached. Bound phages are isolated and separated from the solid matrix by either a change in solution conditions or, for a suitably designed construct, by proteolytic cleavage of a linker region connecting the phage coat protein with the randomized peptide or protein library. The isolated phage can be sequenced to determine the identity of the selected antagonist.

**[0076]** In another embodiment, a polypeptide includes any analog, fragment or chemical derivative of a polypeptide whose amino acid residue sequence is shown herein so long as the polypeptide is an antagonist of FRIP-1 but not of the control peptide of SEQUENCE ID NO: 3. Therefore, a present polypeptide can be subject to various changes, substitutions, insertions, and deletions where such changes provide for certain advantages in its use. In this regard, a FRIP-1 antagonist polypeptide corresponds to, rather than is identical to, the sequence of a recited peptide where one or more changes are made and it retains the ability to function as an antagonist in one or more of the assays as defined herein.

**[0077]** Thus, a polypeptide can be in any of a variety of forms of peptide derivatives, that include amides, conjugates with proteins, cyclized peptides, polymerized peptides, analogs, fragments, chemically modified peptides, and like derivatives.

#### OTHER ANTAGONISTS

**[0078]** Antagonists of the invention method also can be small organic molecules, such as those natural products, or those compounds synthesized by conventional organic synthesis or combinatorial organic synthesis. Compounds can be tested for their ability to modify protein-protein interactions involving certain amino acid sequences within MMP-9 and/or  $\beta 1$  integrin. Compounds also are selected for reduced affinity for the control peptide AAAA, SEQUENCE ID NO: 3.

**[0079]** Antagonists of the invention method also can be non-peptidic compounds. Suitable non-peptidic compounds include, for example, oligonucleotides. Oligonucleotides as used herein refers to any heteropolymeric material containing purine, pyrimidine and other aromatic bases. DNA and RNA oligonucleotides are suitable for use with the invention, as are oligonucleotides with sugar (*e.g.*, 2' alkylated riboses) and backbone modifications (*e.g.*, phosphorothioate oligonucleotides). Oligonucleotides may present commonly found purine and pyrimidine bases such as adenine, thymine, guanine, cytidine and uridine, as well as bases modified within the heterocyclic ring portion (*e.g.*, 7-deazaguanine) or in exocyclic positions. Oligonucleotide also encompasses heteropolymers with distinct structures that also present aromatic bases, including polyamide nucleic acids and the like.

**[0080]** An oligonucleotide antagonist of the invention method can be generated by a number of methods known to one of skill in the art. In one embodiment, a pool of oligonucleotides is generated containing a large number of sequences. Pools can be generated, for example, by solid phase synthesis using mixtures of monomers at an elongation step. The pool of oligonucleotides is sorted by passing a solution containing the pool over a solid matrix to which FRIP-1 or fragment thereof has been affixed. Sequences within the pool that bind to the MMP-9 are retained on the solid matrix. These sequences are eluted with a solution of different salt concentration or pH. Sequences selected are subjected to a second selection step. The selected pool is passed over a second solid matrix to which SEQUENCE ID NO: 3: has been affixed. The column retains those sequences that bind to the SEQUENCE ID NO: 3; thus enriching the pool for sequences specific for FRIP-1. The pool can be amplified and, if necessary, mutagenized and the process repeated until the pool shows the characteristics of an antagonist of the invention. Individual antagonists can be identified by sequencing members of the oligonucleotide pool, usually after cloning said sequences into a host organism such as *E. coli*.

#### BINDING ASSAYS FOR IDENTIFYING ANTAGONISTS

**[0081]** The invention also provides assay methods for identifying candidate antagonists for use according to the invention. In these assay methods candidate antagonists are evaluated for their ability to bind both FRIP-1 and the AAAA control peptide, and furthermore can be evaluated for their potency in inhibiting angiogenesis in a tissue.

#### ELISA

**[0082]** The first assay measures binding of antagonists to FRIP-1 and the AAAA control peptide in the solid phase by

ELISA. The assay also can be used to identify compounds which exhibit specificity for FRIP-1 but not the AAAA control peptide. The specificity assay is conducted by running parallel ELISAs where a potential antagonist is screened concurrently in separate assay chambers for the ability to bind FRIP-1 and the AAAA control peptide.

5 [0083] Antagonists that disrupt the interaction between MMP-9 and  $\alpha 5\beta 1$  integrin can also be identified by their ability to compete for binding with an antagonist of the invention. For example, putative antagonists can be screened by monitoring their effect on the affinity of a known antagonist, such as FM155, in a binding assay, such as ELISA. Such antagonists likely have the same specificity as FM155, and recognize the same cryptic epitope. Putative antagonists selected by such a screening method can bind either to MMP-9 or  $\alpha 5\beta 1$  integrin or to the antagonist. Antagonists can be selected from the putative antagonists by conventional binding assays to determine those that bind to MMP-9 or  
10  $\alpha 5\beta 1$  integrin epitope but not to the known antagonist.

[0084] Following are some embodiments of the invention that can be used to identify candidate antagonists.

[0085] In one embodiment, the invention is a method for screening for MMP-9 antagonists comprising: a) providing a putative antagonist; b) measuring said putative antagonist's first affinity for binding with MMP-9; c) measuring a second affinity of SEQUENCE ID NO: 3 for binding with MMP-9; and d) selecting said putative antagonist as an MMP-9 antagonist if said second affinity is substantially less than said first affinity. In one version of this embodiment, the putative antagonist is a non-peptidic compound, for example, a small organic compound or an oligonucleotide. In another version, the putative antagonist is a polypeptide, a linear peptide or a cyclic peptide. Alternatively, the putative antagonist is an antibody, which could be a monoclonal or polyclonal antibody.

15 [0086] In a preferred embodiment of this method, said first and said second affinities are measured by an enzyme linked immunosorbent assay.

[0087] In one particular embodiment, the second affinity is about 3 times less than the first affinity. Alternatively, the second affinity is about 5 times less than the first affinity. In a further embodiment of the invention, the second affinity is about 10 times less than the first affinity.

20 [0088] In one embodiment, the invention is a method for screening for  $\beta 1$  integrin antagonists comprising: a) providing a putative antagonist; b) measuring said putative antagonist's first affinity for binding with a  $\beta 1$  integrin; c) measuring a second affinity of SEQUENCE ID NO: 3 for binding with said  $\beta 1$  integrin; and d) selecting said putative antagonist as the  $\beta 1$  integrin antagonist if said second affinity is substantially less than said first affinity. In one version of this embodiment, the putative antagonist is a non-peptidic compound, for example, a small organic compound or an oligonucleotide. In another version, the putative antagonist is a polypeptide, a linear peptide or a cyclic peptide. Alternatively, the putative  
25 antagonist is an antibody, which could be a monoclonal or polyclonal antibody.

30 [0089] In a preferred embodiment of this method, said first and said second affinities are measured by an enzyme linked immunosorbent assay.

[0090] In one particular embodiment, the second affinity is about 3 times less than the first affinity. Alternatively, the second affinity is about 5 times less than the first affinity. In a further embodiment of the invention, the second affinity is about 10 times less than the first affinity.  
35

#### ANGIOGENESIS ASSAYS

40 [0091] Antagonists of the invention also can be assayed for their ability to modulate angiogenesis in a tissue. Any suitable assay known to one of skill in the art can be used to monitor such effects. Several such techniques are described herein.

[0092] For example, one assay measures angiogenesis in the chick chorioallantoic membrane (CAM) and is referred to as the CAM assay. The CAM assay has been described in detail by others, and further has been used to measure both angiogenesis and neovascularization of tumor tissues. See Ausprunk et al., Am. J. Pathol., 79:597-618 (1975) and  
45 Ossonski et al., Cancer Res., 40:2300-2309 (1980).

[0093] The CAM assay is a well recognized assay model for *in vivo* angiogenesis because neovascularization of whole tissue is occurring, and actual chick embryo blood vessels are growing into the CAM or into the tissue grown on the CAM.

[0094] As demonstrated herein, the CAM assay illustrates inhibition of neovascularization based on both the amount and extent of new vessel growth. Furthermore, it is easy to monitor the growth of any tissue transplanted upon the CAM, such as a tumor tissue. Finally, the assay is particularly useful because there is an internal control for toxicity in the assay system. The chick embryo is exposed to any test reagent, and therefore the health of the embryo is an indication of toxicity.  
50

[0095] A second assay measures angiogenesis is the *in vivo* rabbit eye model and is referred to as the rabbit eye assay. The rabbit eye assay has been described in detail by others, and further has been used to measure both angiogenesis and neovascularization in the presence of angiogenic inhibitors such as thalidomide. See D'Amato et al. (1994) Proc. Natl. Acad. Sci. 91:4082-4085.  
55

[0096] The rabbit eye assay is a well recognized assay model for *in vivo* angiogenesis because the neovascularization process, exemplified by rabbit blood vessels growing from the rim of the cornea into the cornea, is easily visualized

through the naturally transparent cornea of the eye. Additionally, both the extent and the amount of stimulation or inhibition of neovascularization or regression of neovascularization can easily be monitored over time.

[0097] Finally, the rabbit is exposed to any test reagent, and therefore the health of the rabbit is an indication of toxicity of the test reagent.

5 [0098] A fourth assay measures angiogenesis in the chimeric mouse:human mouse model and is referred to as the chimeric mouse assay. The assay has been described in detail by others, and further has been described herein to measure angiogenesis, neovascularization, and regression of tumor tissues. See Yan, et al. (1993) J. Clin. Invest. 91: 986-996.

10 [0099] The chimeric mouse assay is a useful assay model for *in vivo* angiogenesis because the transplanted skin grafts closely resemble normal human skin histologically and neovascularization of whole tissue is occurring wherein actual human blood vessels are growing from the grafted human skin into the human tumor tissue on the surface of the grafted human skin. The origin of the neovascularization into the human graft can be demonstrated by immunohistochemical staining of the neovasculature with human-specific endothelial cell markers.

15 [0100] The chimeric mouse assay demonstrates regression of neovascularization based on both the amount and extent of regression of new vessel growth. Furthermore, it is easy to monitor effects on the growth of any tissue transplanted upon the grafted skin, such as a tumor tissue. Finally, the assay is useful because there is an internal control for toxicity in the assay system. The chimeric mouse is exposed to any test reagent, and therefore the health of the mouse is an indication of toxicity.

## 20 METHODS FOR INHIBITION OF ANGIOGENESIS

[0101] The invention provides for a use of an antagonist for the manufacture of a medicament for the inhibition of angiogenesis in a tissue, and thereby inhibiting events in the tissue which depend upon angiogenesis. Generally, the use comprises administering to the tissue a composition comprising an angiogenesis-inhibiting amount of an antagonist that modifies protein-protein interactions involving certain amino acid sequences within MMP-9 and/or  $\beta 1$  integrins.

25 [0102] As described earlier, angiogenesis includes a variety of processes involving neovascularization of a tissue including "sprouting", vasculogenesis, or vessel enlargement, all of which angiogenesis processes involve disruption of extracellular matrix collagen in blood vessels. With the exception of traumatic wound healing, corpus leuteum formation and embryogenesis, it is believed that the majority of angiogenesis processes are associated with disease processes and therefore the uses are selective for the disease.

30 [0103] There are a variety of diseases in which angiogenesis is believed to be important, referred to as angiogenic diseases, including but not limited to, inflammatory disorders such as immune and non-immune inflammation, chronic articular rheumatism and psoriasis, disorders associated with inappropriate or inopportune invasion of vessels such as diabetic retinopathy, neovascular glaucoma, restenosis, capillary proliferation in atherosclerotic plaques and osteoporosis, and cancer associated disorders, such as solid tumors, solid tumor metastases, angiofibromas, retrorenal fibroplasia, hemangiomas, Kaposi's sarcoma and the like cancers which require neovascularization to support tumor growth. Other suitable tumors include melanoma, carcinoma, sarcoma, fibrosarcoma, glioma and astrocytoma.

35 [0104] Thus, methods which inhibit angiogenesis in a diseased tissue ameliorate symptoms of the disease and, depending upon the disease, can contribute to cure of the disease. In one embodiment, the invention contemplates inhibition of angiogenesis, *per se*, in a tissue.

40 [0105] As described herein, any of a variety of tissues, or organs comprised of organized tissues, can support angiogenesis in disease conditions including skin, muscle, gut, connective tissue, joints, bones and the like tissue in which blood vessels can invade upon angiogenic stimuli. Tissue, as used herein, also encompasses all bodily fluids, secretions and the like, such as serum, blood, cerebrospinal fluid, plasma, urine, synovial fluid, vitreous humor.

45 [0106] Thus, in one related embodiment, a tissue to be treated is an inflamed tissue and the angiogenesis to be inhibited is inflamed tissue angiogenesis where there is neovascularization of inflamed tissue. In this class the invention use contemplates inhibition of angiogenesis in arthritic tissues, such as in a patient with chronic articular rheumatism, in immune or non-immune inflamed tissues, in psoriatic tissue and the like.

50 [0107] The patient treated is desirably a human patient, although it is to be understood that the principles of the invention indicate that the invention is effective with respect to all mammals, which are intended to be included in the term "patient". In this context, a mammal is understood to include any mammalian species in which treatment of diseases associated with angiogenesis is desirable, particularly agricultural and domestic mammalian species. Such a patient can be, for example, a pig, a cow, a horse, a goat, a sheep, a mule, a donkey, a dog, a cat, a rabbit, a mouse and a rat.

55 [0108] In another related embodiment, a tissue contemplated is a retinal tissue of a patient with diabetic retinopathy, macular degeneration or neovascular glaucoma and the angiogenesis to be inhibited is retinal tissue angiogenesis where there is neovascularization of retinal tissue.

[0109] In an additional related embodiment, a tissue is a tumor tissue of a patient with a solid tumor, a metastases, a skin cancer, a breast cancer, a hemangioma or angiofibroma and the like cancer, and the angiogenesis to be inhibited

is tumor tissue angiogenesis where there is neovascularization of a tumor tissue. Typical solid tumor tissues treatable by the present methods include lung, pancreas, breast, colon, laryngeal, ovarian, Kaposi's Sarcoma and the like tissues. Exemplary tumor tissue angiogenesis, and inhibition thereof, is described in the Examples.

5 [0110] Inhibition of tumor tissue angiogenesis is particularly preferred because of the important role neovascularization plays in tumor growth. In the absence of neovascularization of tumor tissue, the tumor tissue does not obtain the required nutrients, slows in growth, ceases additional growth, regresses and ultimately becomes necrotic resulting in killing of the tumor.

[0111] Stated in other words, the present invention contemplates inhibiting tumor neovascularization by inhibiting tumor angiogenesis. Similarly, the invention contemplates inhibiting tumor growth by angiogenesis-inhibiting.

10 [0112] By their ability to inhibit neovascularization, the uses of the invention also are effective against the formation of metastases because (1) their formation requires vascularization of a primary tumor so that the metastatic cancer cells can exit the primary tumor and (2) their establishment in a secondary site requires neovascularization to support growth of the metastases.

15 [0113] In a related embodiment, the invention use is contemplated in conjunction with other therapies such as conventional chemotherapy directed against solid tumors and for control of establishment of metastases. The administration of angiogenesis inhibitor is typically conducted during or after chemotherapy, although it is preferable to inhibit angiogenesis after a regimen of chemotherapy at times where the tumor tissue will be responding to the toxic assault by inducing angiogenesis to recover by the provision of a blood supply and nutrients to the tumor tissue. In addition, it is preferred to administer the angiogenesis inhibition methods after surgery where solid tumors have been removed as a prophylaxis against metastases.

20 [0114] Insofar as the present uses apply to inhibition of tumor neovascularization, the uses also can apply to regression of established tumors.

25 [0115] Restenosis is a process of smooth muscle cell (SMC) migration and proliferation at the site of percutaneous transluminal coronary angioplasty which hampers the success of angioplasty. The migration and proliferation of SMCs associated with blood vessels during restenosis is related to the process of angiogenesis which is inhibited by the present uses. Therefore, the invention also contemplates inhibition of restenosis by inhibiting angiogenic related processes in a patient following angioplasty procedures. For inhibition of restenosis, the antagonist of the invention uses is typically administered after the angioplasty procedure for from about 2 to about 28 days, and more typically for about the first 14 days following the procedure.

30 [0116] The present use for inhibiting angiogenesis in a tissue, and therefore also the use for treatment of angiogenesis-related diseases, comprises contacting a tissue in which angiogenesis is occurring, or is at risk for occurring, with a therapeutic composition comprising a therapeutically effective amount of an antagonist that modifies protein-protein interactions involving certain amino acid sequences within MMP-9 and/or  $\beta$ 1 integrins. Thus, the use contemplates administering to a patient a therapeutically effective amount of a physiologically tolerable composition containing an antagonist of the invention, which antagonist modifies protein-protein interactions involving certain amino acid sequences within MMP-9 and/or  $\beta$ 1 integrins. Therapeutic compositions and therapeutically effective amounts of antagonists of the invention are described *infra* in the section entitled "Therapeutic Compositions."

35 [0117] The dosage ranges for the administration of the antagonist depend upon the form of the antagonist, and its potency, as described further herein, and are amounts large enough to produce the desired effect in which angiogenesis and the disease symptoms mediated by angiogenesis are ameliorated. The dosage should not be so large as to cause adverse side effects, such as hyperviscosity syndromes, pulmonary edema, congestive heart failure, and the like. Generally, the dosage will vary with the age, condition, sex and extent of the disease in the patient and can be determined by one of skill in the art. The dosage also can be adjusted by the individual physician in the event of any complication.

40 [0118] The monoclonal antibodies of the invention uses can be administered parenterally by injection or by gradual infusion over time. Although the tissue to be treated can typically be accessed in the body by systemic administration and therefore most often treated by intravenous administration of therapeutic compositions, other tissues and delivery means are contemplated where there is a likelihood that the tissue targeted contains the target molecule. Thus, antagonists including monoclonal antibodies, polypeptides, and derivatives thereof can be administered intravenously, intraperitoneally, intramuscularly, subcutaneously, intracavity, transdermally, topically, intraocularly, orally, intranasally and can be delivered by peristaltic means.

45 [0119] The therapeutic compositions containing a monoclonal antibody or a polypeptide of this invention are conventionally administered intravenously, as by injection of a unit dose, for example. The term "unit dose" when used in reference to a therapeutic composition of the present invention refers to physically discrete units suitable as unitary dosage for the subject, each unit containing a predetermined quantity of active material calculated to produce the desired therapeutic effect in association with the required diluent; i.e., carrier, or vehicle.

50 [0120] In one preferred embodiment as shown in the Examples, the antagonist is administered in a single dosage intravenously.

[0121] The compositions are administered in a manner compatible with the dosage formulation, and in a therapeutically

effective amount. The quantity to be administered and timing depends on the patient to be treated, capacity of the patient's system to utilize the active ingredient, and degree of therapeutic effect desired. Precise amounts of active ingredient required to be administered depend on the judgement of the practitioner and are peculiar to each individual. However, suitable dosage ranges for systemic application are disclosed herein and depend on the route of administration. Suitable regimes for administration also are variable, but are typified by an initial administration followed by repeated doses at one or more hour intervals by a subsequent injection or other administration. Alternatively, continuous intravenous infusion sufficient to maintain concentrations in the blood in the ranges specified for *in vivo* therapies are contemplated.

**[0122]** As specific examples of uses for inhibiting angiogenesis or disease states, the following embodiments of the invention are offered.

**[0123]** In one embodiment, the invention is a use of an antagonist for the manufacture of a medicament for inhibiting angiogenesis in a tissue comprising administering an antagonist that specifically modifies protein-protein interactions, wherein the protein-protein interactions comprise interactions between at least one amino acid sequence within a first protein and at least one amino acid sequence within a second protein. In this use, said antagonist is administered intravenously, transdermally, intrasynovially, intramuscularly, intratumorally, intraocularly, intranasally, intrathecally, topically or orally. Further, the antagonist may be administered in conjunction with chemotherapy or in conjunction with radiation. This method is used when the tissue is inflamed and angiogenesis is occurring, when the tissue is present in a mammal, or when the tissue is arthritic, ocular, retinal or a hemangioma.

**[0124]** In another use according to the invention, tumor growth or metastasis in a tissue is inhibited in a use comprising administering an antagonist that specifically modifies protein-protein interactions, wherein the protein-protein interactions comprise interactions between at least one amino acid sequence within a first protein and at least one amino acid sequence within a second protein. In such a method, said antagonist is administered intravenously, transdermally, intrasynovially, intramuscularly, intratumorally, intraocularly, intranasally, topically or orally. Further, the antagonist may be administered in conjunction with chemotherapy or in conjunction with radiation. This use would be applicable when the tumor or metastasis is a melanoma, carcinoma, sarcoma, fibrosarcoma, glioma or In another embodiment, the invention is a use of inhibiting psoriasis, macular degeneration, or restenosis in a tissue by administering an antagonist that specifically modifies protein-protein interactions, wherein the protein-protein interactions comprise interactions between at least one amino acid sequence within a first protein and at least one amino acid sequence within a second protein. In this use, said antagonist is administered intravenously, transdermally, intrasynovially, intramuscularly, intratumorally, intraocularly, intranasally, intrathecally, topically or orally. Further, the antagonist is administered in conjunction with chemotherapy or in conjunction with astrocytoma.

## DISEASE TREATMENT

**[0125]** The present invention relates generally to the discovery that modifying protein-protein interactions involving certain amino acid sequences within MMP-9 and/or  $\beta 1$  integrins inhibits disease states and angiogenesis. This discovery is important because of the role that angiogenesis plays in a variety of disease processes.

**[0126]** Where the growth of new blood vessels is the cause of, or contributes to, the pathology associated with a disease, inhibition of angiogenesis will reduce the deleterious effects of the disease. Examples include psoriasis, rheumatoid arthritis, diabetic retinopathy, inflammatory diseases, restenosis, macular degeneration and the like. Where the growth of new blood vessels is required to support growth of a deleterious tissue, inhibition of angiogenesis will reduce the blood supply to the tissue and thereby contribute to reduction in tissue mass based on blood supply requirements. Examples include growth of tumors where neovascularization is a continual requirement in order that the tumor grow beyond a few millimeters in thickness, and for the establishment of solid tumor metastases.

**[0127]** The uses of the present invention are effective in part because the therapy is highly selective for angiogenesis and not other biological processes. As shown in the Examples, only new vessel growth is inhibited by antagonists that disrupt the localization of MMP-9, and therefore the therapeutic uses do not adversely effect mature vessels. Also, because certain of the the antagonists of the invention affect only the localization of MMP-9, and do not directly block the proteolytic activity of MMP-9 or the adhesive functions of the  $\beta 1$  integrins, it is likely that these compounds will have fewer side effects because the proteolytic activity of MMP-9 or the adhesive functions of the  $\beta 1$  integrins may have normal physiological functions.

**[0128]** Moreover, the antagonists of the invention are highly potent suggesting that they may have therapeutic benefits at low concentrations.

**[0129]** Prior to the discoveries of the present invention, it was not known that angiogenesis, and any of the processes dependent on angiogenesis, could be inhibited *in vivo* by the use of reagents that antagonize the interaction between MMP-9 and the  $\beta 1$  integrins.

## THERAPEUTIC COMPOSITIONS

5 [0130] The present invention contemplates therapeutic compositions useful for the uses described herein. Therapeutic compositions contain a physiologically tolerable carrier together with a therapeutically effective amount of an antagonist as described herein, dissolved or dispersed therein as an active ingredient. In a preferred embodiment, the therapeutic antagonist composition is not immunogenic or has reduced immunogenicity when administered to a mammal or human patient for therapeutic purposes.

10 [0131] A therapeutically effective amount is an amount of an antagonist of the invention sufficient to produce a measurable inhibition of angiogenesis in the tissue being treated, i.e., an angiogenesis-inhibiting amount. Inhibition of angiogenesis can be measured *in situ* by immunohistochemistry, as described herein, or by other methods known to one skilled in the art.

[0132] Potency of an antagonist of the invention can be measured by a variety of means including inhibition of angiogenesis in the CAM assay, in the *in vivo* rabbit eye assay, in the *in vivo* chimeric mouse:human assay and the assays.

15 [0133] A therapeutically effective amount of an antagonist of this invention in the form of a monoclonal antibody is typically an amount such that when administered in a physiologically tolerable composition is sufficient to achieve a plasma concentration of from about 0.01 microgram (ug) per milliliter (mL) to about 100 ug/mL, preferably from about 1 ug/mL to about 5 ug/mL, and usually about 5 ug/mL. Stated differently, the dosage can vary from about 0.1 mg/kg to about 300 mg/kg, preferably from about 0.2 mg/kg to about 200 mg/kg, most preferably from about 0.5 mg/kg to about 20 mg/kg, in one or more dose administrations daily, for one or several days.

20 [0134] Where the antagonist is in the form of a fragment of a monoclonal antibody, the amount can readily be adjusted based on the mass of the fragment relative to the mass of the whole antibody. A preferred plasma concentration in molarity is from about 2 micromolar (uM) to about 5 millimolar (mM) and preferably about 100 uM to 1 mM antibody antagonist.

25 [0135] A therapeutically effective amount of an antagonist in the form of a polypeptide, or small molecule, is typically an amount of polypeptide such that when administered in a physiologically tolerable composition is sufficient to achieve a plasma concentration of from about 0.1 microgram (ug) per milliliter (mL) to about 200 ug/mL, preferably from about 1 ug/mL to about 150 ug/mL. Based on a polypeptide having a mass of about 500 grams per mole, the preferred plasma concentration in molarity is from about 2 micromolar (uM) to about 5 millimolar (mM) and preferably about 100 uM to 1 mM polypeptide antagonist. Stated differently, the dosage per body weight can vary from about 0.1 mg/kg to about 300 mg/kg, and preferably from about 0.2 mg/kg to about 200 mg/kg, in one or more dose administrations daily, for one or several days.

30 [0136] As used herein, the terms "pharmaceutically acceptable", "physiologically tolerable" and grammatical variations thereof, as they refer to compositions, carriers, diluents and reagents, are used interchangeably and represent that the materials are capable of administration to or upon a mammal.

35 [0137] The preparation of a pharmacological composition that contains active ingredients dissolved or dispersed therein is well understood in the art and need not be limited based on formulation. Typically such compositions are prepared as injectables either as liquid solutions or suspensions, however, solid forms suitable for solution, or suspensions, in liquid prior to use also can be prepared. The preparation also can be emulsified.

40 [0138] The active ingredient can be mixed with excipients which are pharmaceutically acceptable and compatible with the active ingredient and in amounts suitable for use in the therapeutic methods described herein. Suitable excipients are, for example, water, saline, dextrose, glycerol, ethanol or the like and combinations thereof. In addition, if desired, the composition can contain minor amounts of auxiliary substances such as wetting or emulsifying agents, pH buffering agents and the like which enhance the effectiveness of the active ingredient.

45 [0139] The therapeutic composition can include pharmaceutically acceptable salts of the components therein. Pharmaceutically acceptable salts include the acid addition salts (formed with the free amino groups of a polypeptide) that are formed with inorganic acids such as, for example, hydrochloric or phosphoric acids, or such organic acids as acetic, tartaric, mandelic and the like. Salts formed with the free carboxyl groups also can be derived from inorganic bases such as, for example, sodium, potassium, ammonium, calcium or ferric hydroxides, and such organic bases as isopropylamine, trimethylamine, 2-ethylamino ethanol, histidine, procaine and the like. Particularly preferred are the salts of TFA and HCl.

50 [0140] Physiologically tolerable carriers are well known in the art. Exemplary of liquid carriers are sterile aqueous solutions that contain no materials in addition to the active ingredients and water, or contain a buffer such as sodium phosphate at physiological pH value, physiological saline or both, such as phosphate-buffered saline. Still further, aqueous carriers can contain more than one buffer salt, as well as salts such as sodium and potassium chlorides, dextrose, polyethylene glycol and other solutes.

55 [0141] Liquid compositions also can contain liquid phases in addition to and to the exclusion of water. Exemplary of such additional liquid phases are glycerin, vegetable oils such as cottonseed oil, and water-oil emulsions.

[0142] A therapeutic composition contains an angiogenesis-inhibiting amount of an antagonist of the present invention, typically formulated to contain an amount of at least 0.01 weight percent of antagonist per weight of total therapeutic

composition. A weight percent is a ratio by weight of inhibitor to total composition. Thus, for example, 0.01 weight percent is 0.01 grams of inhibitor per 100 grams of total composition.

[0143] An antibody can be conjugated with cytotoxins, cytotoxic agents, for delivery to a tumor or other tissue undergoing angiogenesis. Such conjugates can be made with a cytotoxin or an exotoxin, for example ricin A, diphtheria toxin A, or *Pseudomonas* exotoxin and fragments thereof. The cytotoxic agent can also be radioactively labeled with an isotope so as to locally deliver a toxic dose of radioactivity to an angiogenic tissue.

[0144] Antagonists of the invention can also be used to deliver an enzyme to a target wherein the enzyme is capable of converting a prodrug into an active form of the drug for use in, for example, antibody-directed enzyme activated prodrug therapy (ADEPT) (see, e.g., Syrigos, K.N. (1999) *Anticancer Res.* 19:605-13). Briefly, an antagonist of the invention is conjugated with an enzyme, such as a lactamase, protease or esterase, that can convert a non-toxic or inactive prodrug into a toxic or active drug. Because the antagonist of the invention localizes to sites of angiogenesis, and particularly to sites of tumors or metastases, toxic drugs can be directed to such sites

## DETECTION METHODS

[0145] Antagonists of the invention also are suitable for detection of angiogenesis in tissues. For example, where the antagonist is an antibody, the antagonist can be used in immunohistochemical techniques to stain tissues *ex vivo*. Immunological techniques such as immunostaining and ELISA are described in, for example, *Receptor Binding Techniques, Methods in Molecular Biology*. 106. ed. M. Keen. Humana Press, 1999; Brooks et al. (1998) *Cell* 92:391-400; Brooks et al. (1996) *Cell* 85:683-693; and Brooks et al. (1993) *J. Cell. Biol.* 122:1351-1359.

[0146] The antagonist of the invention, once bound to the target tissue can be detected either directly or indirectly. Direct detection can be performed on antagonists that comprise a detectable label such as a fluorochrome, a radioactive tag, paramagnetic heavy metal or diagnostic dye.

[0147] Alternatively, detection can occur through a secondary interaction. For example, a detectably labeled antibody that recognizes the antagonist can be used to visualize the location of the antagonist. For example, if the antagonist is a monoclonal antibody of mouse origin, a goat anti-mouse antibody that is suitably labeled can be used. One of skill in the art can determine suitable secondary antibodies for use with various antagonists.

[0148] For *in vivo* detection, it is preferable to use a detectably labeled antagonist. The labeled antagonist is administered to a patient intravenously, intramuscularly, etc. Labels suitable for detection within a patient are particularly preferred. For example, paramagnetically labeled antagonists can be detected by magnetic resonance imaging. Radioactively tagged antagonists also can be detected.

[0149] Examples of specific embodiments of the invention suitable for detection are as follows.

[0150] In one embodiment, the invention is a use of an antagonist for the manufacture of a medicament for detecting angiogenesis in a tissue by contacting an antagonist that specifically modifies protein-protein interactions, wherein the protein-protein interactions comprise interactions between at least one amino acid sequence within a first protein and at least one amino acid sequence within a second protein with said tissue. In this use, for example, said tissue is *ex vivo* or said tissue is *in vivo* and said antagonist is administered intravenously, transdermally, intrasynovially, intramuscularly, intratumorally, intraocularly, intranasally, intrathecally, topically or orally. Alternatively, in this use said antagonist is conjugated to a fluorochrome, radioactive tag, paramagnetic heavy metal, diagnostic dye or enzyme.

## EXAMPLES

### EXAMPLE 1

#### Purification of $\alpha 5\beta 1$ .

[0151]  $\alpha 5\beta 1$  was purified from placental lysates utilizing the 110kD cell binding domain of fibronectin. Eluted fractions were concentrated and separated by 10% SDS PAGE followed by silver staining. A 90kD protein co-purifies with integrin  $\alpha 5\beta 1$  with a molecular weight same as MMP-9 as shown in Figure 1. In the figure, Lane 1 corresponds to commercially prepared human  $\alpha 5\beta 1$  (1  $\mu$ g) and Lane 2 to  $\alpha 5\beta 1$  (50  $\mu$ l) purified from human placental tissue. Note minor 90kD contaminate (arrow).

[0152] Based on our previous finding of a direct interaction between MMP-2 and  $\alpha 5\beta 3$ , we examined whether this 90kD protein may be another example of MMP binding to an integrin.

**EXAMPLE 2****Zymographic Analysis of  $\alpha 5\beta 1$ .**

5 [0153] Purified  $\alpha 5\beta 1$  and  $\alpha v\beta 3$  were separated on 10% SDS PAGE gels co-polymerized with gelatin. SDS was removed from the gels by washing in Triton X-100 and the gels were incubated in collagenase buffer. Gelatinolytic bands were visualized by staining with coomassie blue. The purified  $\alpha 5\beta 1$  preparation contains gelatinolytic activity (90kD) that migrates at the same molecular weight as MMP-9 as shown in Figure 2. In the figure, Lane 1 corresponds to Pro MMP-9 (1 $\mu$ g), Lane 2 to APMA activated MMP-9 (1 $\mu$ g), Lane 3 to prep-1 purified  $\alpha 5\beta 1$  from placental tissue (1 $\mu$ g); Lane 4 to purified  $\alpha v\beta 3$  from placental tissue (1 $\mu$ g) and Lane 5 to prep-2 purified  $\alpha 5\beta 1$  from placental tissue (1 $\mu$ g).  
 10 [0154] These data suggest that the contaminating 90kD protein that co-purified with a  $\alpha 5\beta 1$  may be MMP-9. Moreover, these studies suggest that MMP-9 may bind directly to integrin  $\alpha 5\beta 1$ .

**EXAMPLE 3**

15 **Western Blot Analysis of Purified Integrins  $\alpha 5\beta 1$ .**

[0155] Purified integrins  $\alpha 5\beta 1$  and  $\alpha v\beta 3$  (1 $\mu$ g) were separated by 10% SDS PAGE and transferred to nitrocellulose and blotted with anti-MMP-9 Mab. Western blot analysis of the purified  $\alpha 5\beta 1$ , shown in Figure 3, with a monoclonal antibody directed to MMP-9 confirms the existence of MMP-9 within the preparation of  $\alpha 5\beta 1$ . In Figure 3, Lane 1 corresponds to Recombinant MMP-9 (1 $\mu$ g), Lane 2 to purified  $\alpha 5\beta 1$  from placental tissue (1 $\mu$ g) and Lane 3 to purified  $\alpha 5\beta 1$  from placental tissue (1 $\mu$ g).  
 20

**EXAMPLE 4**

25 **Recombinant MMP-9 Binds to  $\alpha 5\beta 1$ .**

[0156]  $\alpha 5\beta 1$  or control protein  $\beta$ -casein was immobilized on microtiter wells (10 $\mu$ g/ml). Recombinant human MMP-9 (2 $\mu$ g/ml) was allowed to bind to control coated wells for one hour. MMP-9 binding was detected with anti-MMP-9 Mab. As can be seen from Figure 4, purified MMP-9 binds directly to integrin  $\alpha 5\beta 1$ . Data Bars represent the mean optical density  $\pm$  standard deviations from triplicate wells.  
 30

**EXAMPLE 5**

35 **Reduced MMP-9 Binding to the Surface of  $\alpha 5\beta 1$  Negative Cells.**

[0157] To evaluate whether  $\alpha 5\beta 1$  may be involved in facilitating binding of MMP-9 to the cell surface, binding assays were performed. Human HT29 cells that express little if any endogenous MMP-9 were incubated with recombinant MMP-9 (0 to 100ng/ml). Non-bound enzyme was removed and total cell lysates were prepared. Cell lysates (100 $\mu$ g per lane) were separated on a 10% SDS PAGE gel co-polymerized with gelatin and gelatinolytic bands were visualized by staining with coomassie blue. The results shown in Figure 5 suggest that tumor cells lacking  $\alpha 5\beta 1$  have a significantly reduced capacity to bind MMP-9, providing further evidence that  $\alpha 5\beta 1$  may play an important role in localizing proteolytic activity to the cell surface. In the figure, Top corresponds to  $\alpha 5\beta 1$  expressing HT29-30, Bottom to  $\alpha 5\beta 1$  negative HT29-1, NT to no treatment, 50 to Cells incubated with 50ng/ml of MMP-9 and 100 to Cells incubated with 100ng/ml of MMP-9.  
 40  
 45

**EXAMPLE 6****Co-Localization of MMP-9 and  $\alpha 5\beta 1$  in Human Melanoma Tumor Blood Vessels.**

50 [0158] Human biopsies from melanoma patients were snap frozen and tissue sections were co-stained with a polyclonal antibody directed to MMP-9 and a monoclonal antibody directed to  $\beta 1$ , followed by incubation with both rhodamine conjugated goat-anti-mouse and FITC conjugated goat-anti-rabbit IgGs. Photomicrographs were taken at 200X. In the photomicrograph, red indicated  $\beta 1$  integrin expression, green indicated MMP-9 expression, yellow indicated co-localization of MMP-9 and  $\beta 1$ . In Figure 6, which is a black and white reproduction of the photomicrograph, the white regions represent yellow, and the black regions represent red, green, or the tumor cells. Figure 6 shows that MMP-9 and  $\beta 1$  integrins co-localize on the tumor cell surface and blood vessels within human melanoma tumor biopsies.  
 55 [0159] These findings suggest that MMP-9 and  $\beta 1$  integrins are closely associated within both the human vascular compartment as well as on the tumor cells themselves.

**EXAMPLE 7****Generation of Synthetic Peptides That Bind to MMP-9.**

5 **[0160]** Analysis of the amino acid sequences of both MMP-9 and  $\alpha 5\beta 1$  suggested sequences that may mediate the interaction between these two proteins. For example, synthetic peptides were generated and analyzed for binding activity to MMP-9. The binding ability of the peptides was analyzed by solid phase binding assays.

**[0161]** Among the sequences analyzed, peptides were found that showed binding specificity for MMP-9 or the  $\beta 1$  integrins. Thus, as shown in Figure 7, the peptide termed FRIP-1 was shown to specifically bind to MMP-9 in solid phase binding assays. AAA peptide which was identical to FRIP-1 except that 3 key amino acids were changed showed little in any binding ability. These findings suggest that the synthetic peptide FRIP-1 likely represents key amino acids involved in mediating MMP-9/ $\alpha 5\beta 1$  interactions.

**[0162]** FRIP-1 synthetic peptide has the sequence: SEQ ID NO: 1: CysArgLeuArgSerGlyGluProGlnCys

10 **[0163]** The FRIP1 (SEQ ID NO: 1) amino acid sequence was derived from a region within the C-terminal hemopexin-like domain of human enzyme MMP-9.

**[0164]** The AAA control peptide has the following sequence: SEQ ID NO: 2: CysArgAlaAlaAlaGlyGluProGlnCys

15 **[0165]** Binding controls were also performed with a AAAA control peptide with the following sequence: SEQ ID NO: 3: CysArgAlaAlaAlaAlaGluProGlnCys.

20 **EXAMPLE 8****FRIP-1 Peptide Inhibits Angiogenesis in the Chick Embryo.**

25 **[0166]** Angiogenesis was induced on the CAMs of 10 day old chick embryos with bFGF. Twenty-four hours later the embryos received a single IV injection with 100 $\mu$ g of FRIP-1 or AAA control peptide. Three days later angiogenesis was quantified by counting the number of blood vessel branch points within the area of the filter disc. Figure 8A shows representative examples of CAM tissue from a typical experiment. Figure 8B is a quantification of the angiogenesis experiments. The results in Figure 8B show that the FRIP-1 synthetic peptide that binds to MMP-9 blocks angiogenesis in the Chick Embryo CAM Model. In Figure 8B, the label "bFGF" corresponds to an experiment where angiogenesis was induced by a treatment with bFGF and no further treatment followed. The "FRIP-1 Treatment" label refers to a treatment with FRIP-1 peptide that followed an induction of the angiogenesis by a treatment with bFGF. The "Control" label refers to an experiment, in which a treatment with a control AAA peptide followed an induction of the angiogenesis by a treatment with bFGF. Data bars represent the mean  $\pm$  standard errors of 5 to 10 embryos per condition.

30 **[0167]** This data suggests that MMP-9/ $\alpha 5\beta 1$  interaction may play an important role in angiogenesis.

35 **EXAMPLE 9****Generation of Mabs Directed to Synthetic Peptides.**

40 **[0168]** FRIP-1 peptide was conjugated to the carrier protein KLH and injected into mice. Conditioned medium from 5 representative hybridoma clones were analyzed by ELISA for binding to FRIP-1 peptide or control AAA peptide. The data, shown in Figure 9, represents the mean relative binding (optical density)  $\pm$  standard deviation from triplicate wells.

**[0169]** A number of Mabs were generated, as shown in Figure 9, to the FRIP-1 peptide and some of these antibodies, for example Mab FM155, showed high specificity to the FRIP-1 peptide but did not react with the control peptide AAA. Thus, Mab FM155 was chosen for further evaluation.

45 **EXAMPLE 10****Effects of Mab FM155 on MMP-9/ $\alpha 5\beta 1$  Interactions. Conclusions:**

50 **[0170]**  $\alpha 5\beta 1$  was immobilized on microtiter wells (10 $\mu$ g/ml). Recombinant human MMP-9 (2 $\mu$ g/ml) was allowed to bind in the presence or absence of Mabs FM155 or LM609. MMP-9 binding was detected with anti-MMP-9 polyclonal antibody. The results are shown in Figure 10. Data bars represent the mean optical density  $\pm$  standard deviations from triplicate wells. In the figure, the label "MMP-9" corresponds to MMP-9 binding in the absence of antibodies FM155 and LM609. The label "MMP-9 +FM155" refers to MMP-9 binding in the presence of FM155 antibody. The label "MMP-9 +LM609" refers to MMP-9 binding in the presence of LM609 antibody. FM155 is anti FRIP-1 and LM609 is anti- $\alpha v\beta 3$  Mab.

55 **[0171]** Figure 10 shows that Mab FM155 specifically blocked the ability of MMP-9 to bind to purified  $\alpha 5\beta 1$  suggesting that FM155 can be used to disrupt this interaction in vivo.

EXAMPLE 11

Effects of Systemic Administration of FM155 on Melanoma Tumor Growth.

5 [0172] CS-1 melanoma cells ( $5 \times 10^6$ ) were inoculated on the CAMs of 10 day old chick embryos. Twenty-four hours later, the embryos received a single intravenous injection of purified Mab FM 155 (2.0 $\mu$ g, 10.0 $\mu$ g, 50.0 $\mu$ g) After 7 days tumors were resected and wet weights determined. Figure 11 presents the quantification of tumors' weight. Data bars represent the mean  $\pm$  the standard errors from 5 to 10 embryos per condition. NT represents data for no treatment.

10 [0173] Figure 11 illustrates that Mab FM155 potently inhibits CS-1 melanoma tumor growth in vivo. These findings indicate that the blocking of the interactions of MMP-9 and  $\alpha 5\beta 1$  may play a significant role in regulating angiogenesis and tumor growth in vivo.

[0174] It is also to be appreciated that the foregoing description of the invention has been presented for purposes of illustration and explanation and is not intended to limit the invention to the precise manner of practice herein.

15 SEQUENCE LISTING

[0175]

20 <110> University of Southern California  
Brooks, Peter C.  
Hassanieh, Loubna  
Rodriguez, Dorothy

25 <120> NOVEL METHOD AND COMPOSITION FOR INHIBITION OF ANGIOGENESIS USING ANTAGONISTS  
BASED ON MMP-9 AND BETA 1 INTEGRINS

<130> 13761-734PCT

30 <140> Not Yet Assigned  
<141>

<150> US 60/143,581  
<151> 1999-07-13

35 <150> US 60/152,495  
<151> 1999-09-02

<160> 3

40 <170> FastSEQ for Windows Version 4.0

<210> 1  
<211> 10  
<212> PRT

45 <213> Artificial Sequence

<220>  
<223> Synthetic sequence, FRIP-1

50 <223> Binds to MMP-9 and beta 1 integrins.

<400> 1

55 Cys Arg Leu Arg Ser Gly Glu Pro Gln Cys  
1 5 10

<210> 2



## EP 1 203 025 B1

9. The antagonist of claim 1 wherein the antagonist is conjugated to cytotoxic or cytostatic agents.
10. Use of the antagonist of claim 8 for manufacture of a medicament for inhibiting angiogenesis, tumor growth, metastasis, psoriasis, macular degeneration, or restenosis in a tissue.
- 5 11. Use according to claim 10 wherein said antagonist is administered intravenously, transdermally, intrasynovially, intramuscularly, intratumorally, intraocularly, intranasally, intrathecally, topically or orally.
- 10 12. Use according to claim 10 wherein said antagonist is administered in conjunction with chemotherapy or in conjunction with radiation therapy.
13. Use according to claim 10 wherein the tissue is inflamed and angiogenesis is occurring.
14. Use according to claim 10 wherein the tissue is present in a mammal.
- 15 15. Use according to claim 14 wherein the tissue is arthritic, ocular, retinal or a hemangioma.
16. Use according to claim 10 wherein the tumor or metastasis is a melanoma, carcinoma, sarcoma, fibrosarcoma, glioma or astrocytoma.
- 20 17. Use of the antagonist of claim 8 for the manufacture of a medicament for detecting angiogenesis, tumors or tumor invasion in a tissue by contacting said antagonist with said tissue.
- 25 18. The use of claim 17 wherein said tissue is *ex vivo*.
19. The use of claim 17 wherein said tissue is *in vivo* and said antagonist is administered intravenously, transdermally, intrasynovially, inteamuscularly, intratumorally, intraocularly, intranasally, intrathecally, topically or orally.
- 30 20. The use of claim 17 wherein said antagonist is conjugated to a fluorochrome, radioactive tag, paramagnetic heavy metal, diagnostic dye or enzyme.
21. A method for screening for MMP-9 or  $\beta$ 1 integrin antagonists comprising:
- 35 a) providing a putative antagonist;  
b) measuring said putative antagonist's first affinity for binding with MMP-9 or a  $\beta$ 1 integrin;  
c) measuring a second affinity of SEQ ID NO: 3 for binding with MMP-9 or said  $\beta$ 1 integrin;  
d) selecting said putative antagonist as an MMP-9 or a  $\beta$ 1 integrin antagonist if said second affinity is substantially less than said first affinity.
- 40 22. The method of claim 21 wherein said putative antagonist is a non-peptidic compound.
23. The method of claim 22, wherein said non-peptidic compound is a small organic compound or an oligonucleotide.
- 45 24. The method of claim 21 wherein said putative antagonist is a polypeptide, a linear peptide, a cyclic peptide, or a monoclonal or polyclonal antibody.
25. The method of claim 21 wherein said first and said second affinities are measured by an enzyme linked immunosorbent assay.
- 50 26. The method of claim 21 wherein said second affinity is about 3 times less than said first affinity.
27. The method of claim 21 wherein said second affinity is about 5 times less than said first affinity.
28. The method of claim 21 wherein said second affinity is about 10 times less than said first affinity.
- 55 29. A peptide consisting of the amino acid sequence of SEQ ID NO: 1 comprising an epitope recognized by an antagonist of claim 5.

**Patentansprüche**

- 5 1. Ein Antagonist, welcher Angiogenese durch Modifizieren von Protein-Protein Interaktionen zwischen Matrix-Metalloproteinase 9 (MMP-9) und einem  $\beta$ 1-beihaltenden Integrin verhindert, wobei der Antagonist einen Antikörper umfasst, welcher spezifisch an ein Polypeptid bindet, welches aus der Sequenz von SEQ ID NO: 1 besteht.
2. Der Antagonist des Anspruchs 1, wobei die Protein-Protein Interaktionen MMP-9 veranlassen, an das  $\beta$ 1-beihaltende Integrin zu binden.
- 10 3. Der Antagonist des Anspruchs 1, wobei das  $\beta$ 1-beihaltende Integrin  $\alpha$ 5  $\beta$ 1 Integrin ist.
4. Der Antagonist des Anspruchs 1, 2 oder 3, wobei die Protein-Protein Interaktionen Co-Lokalisierung des MMP-9 und des  $\beta$ 1-beihaltenden Integrins auf einer Zelloberfläche oder einem Blutgefäß bewirken.
- 15 5. Der Antagonist des Anspruchs 1, wobei der Antagonist ein monoklonaler Antikörper oder ein humanisierter monoklonaler Antikörper oder ein funktionelles Fragment davon oder ein chemisch modifizierter, monoklonaler Antikörper oder ein funktionelles Fragment davon ist.
- 20 6. Der Antagonist des Anspruchs 5, wobei das funktionelle Fragment ein Fab, ein Fab', ein F(ab')<sub>2</sub>, oder ein F(v) ist.
7. Der Antagonist des Anspruchs 1, wobei der Antagonist ein polyklonaler Antikörper ist.
8. Der Antagonist des Anspruchs 1, wobei der Antagonist ein monoklonaler Antikörper ist, welcher spezifisch an SEQ ID NO: 1 bindet, aber an SEQ ID NO: 3 mit wesentlich verringerter Affinität bindet.
- 25 9. Der Antagonist des Anspruchs 1, wobei der Antagonist mit einem zytotoxischen oder zytostatischen Mittel konjugiert ist.
- 30 10. Verwendung des Antagonisten des Anspruchs 8 für die Herstellung eines Medikaments zum Hemmen von Angiogenese, Tumorwachstum, Absiedlung, Psoriasis, Makuladegeneration oder Restenose in einem Gewebe.
11. Verwendung gemäß Anspruch 10, wobei der Antagonist intravenös, transdermal, intrasynovial, intramuskulär, intratumoral, intraokular, intranasal, intrathekal, topisch oder oral verabreicht wird.
- 35 12. Verwendung gemäß Anspruch 10, wobei der Antagonist in Verbindung mit Chemotherapie oder in Verbindung mit Strahlentherapie verabreicht wird.
13. Verwendung gemäß Anspruch 10, wobei das Gewebe entzündet ist und Angiogenese auftritt.
- 40 14. Verwendung gemäß Anspruch 10, wobei das Gewebe in einem Säugetier auftritt.
15. Verwendung gemäß Anspruch 14, wobei das Gewebe arthritisch, okular, retinal oder ein Hämangiom ist.
- 45 16. Verwendung gemäß Anspruch 10, wobei der Tumor oder die Absiedlung ein Melanom, Karzinom, Sarkom, Fibrosarkom, Gliom oder Astrozytom ist.
17. Verwendung des Antagonisten des Anspruchs 8 für die Herstellung eines Medikaments zum Detektieren von Angiogenese, Tumoren oder Tumoreindringen in einem Gewebe durch Kontaktieren des Antagonisten mit dem Gewebe.
- 50 18. Die Verwendung des Anspruchs 17, wobei das Gewebe *ex vivo* ist.
19. Die Verwendung des Anspruchs 17, wobei das Gewebe *in vivo* ist und der Antagonist intravenös, transdermal, intrasynovial, intramuskulär, intratumoral, intraokular, intranasal, intrathekal, topisch oder oral verabreicht ist.
- 55 20. Die Verwendung des Anspruchs 17, wobei der Antagonist mit einem Fluorochrom, einer radioaktiven Markierung, einem paramagnetischen Schwermetall, diagnostischen Farbstoff oder Enzym konjugiert ist.

## EP 1 203 025 B1

21. Ein Verfahren zum Screenen nach MMP-9 oder  $\beta$ 1 Integrin Antagonisten umfassend:

- a) Zurverfügungstellen eines putativen Antagonisten;
- b) Messen der ersten Affinität des putativen Antagonisten zur Bindung mit MMP-9 oder einem  $\beta$ 1 Integrin;
- c) Messen einer zweiten Affinität von SEQ ID NO: 3 zur Bindung mit MMP-9 oder dem  $\beta$ 1 Integrin;
- d) Auswählen des putativen Antagonisten als MMP-9 oder  $\beta$ 1 Integrin Antagonist, wenn die zweite Affinität wesentlich geringer ist als die erste Affinität.

22. Verfahren des Anspruchs 21, wobei der putative Antagonist eine nicht-peptidische Verbindung ist.

23. Verfahren des Anspruchs 22, wobei die nicht-peptidische Verbindung eine kleine organische Verbindung oder ein Oligonukleotid ist.

24. Verfahren des Anspruchs 21, wobei der putative Antagonist ein Polypeptid, ein lineares Peptid, ein zyklisches Peptid oder ein monoklonaler oder polyklonaler Antikörper ist.

25. Verfahren des Anspruchs 21, wobei die ersten und die zweiten Affinitäten durch einen enzymgekoppelten Immunsorptionsstest gemessen werden.

26. Verfahren des Anspruchs 21, wobei die zweite Affinität ungefähr dreimal geringer als die erste Affinität ist.

27. Verfahren des Anspruchs 21, wobei die zweite Affinität ungefähr fünfmal geringer als die erste Affinität ist.

28. Verfahren des Anspruchs 21, wobei die zweite Affinität ungefähr zehnmal geringer als die erste Affinität ist.

29. Ein Peptid bestehend aus der Aminosäuresequenz der SEQ ID NO: 1, umfassend ein Epitop, das durch einen Antagonist des Anspruchs 5 erkannt wird.

### Revendications

1. Antagoniste qui inhibe l'angiogénèse en modifiant des Interactions protéine-protéine entre une métalloprotéinase de matrice 9 (MMP-9) et une Intégrine contenant  $\beta$ 1, dans lequel ledit antagoniste comprend un anticorps qui se lie spécifiquement à un polypeptide consistant en la séquence de SEQ ID NO:1,

2. Antagoniste selon la revendication 1, dans lequel les interactions protéine-protéine occasionnent le fait que MMP-9 se lie à l'intégrine contenant  $\beta$ 1.

3. Antagoniste selon la revendication 1, dans lequel l'intégrine contenant  $\beta$ 1 est l' $\alpha$ 5  $\beta$ 1 intégrine.

4. Antagoniste selon la revendication 1, 2 ou 3, dans lequel les interactions protéine-protéine occasionnent une co-localisation de la MMP-9 et de l'intégrine contenant  $\beta$ 1 sur une surface de cellule ou un vaisseau sanguin.

5. Antagoniste selon la revendication 1, dans lequel ledit antagoniste est un anticorps monoclonal ou un anticorps monoclonal humanisé ou un fragment fonctionnel de celui-ci ou un anticorps monoclonal chimiquement modifié ou un fragment fonctionnel de celui-ci.

6. Antagoniste selon la revendication 5, dans lequel le fragment fonctionnel est un Fab, un Fab', un  $F(ab')_2$  ou un F(v).

7. Antagoniste selon la revendication 1, dans lequel l'antagoniste est un anticorps polyclonal.

8. Antagoniste selon la revendication 1, dans lequel ledit antagoniste est un anticorps monoclonal qui se lie spécifiquement avec SEQ ID NO:1 mais qui se lie avec SEQ ID NO:3 avec une affinité sensiblement réduite.

9. Antagoniste selon la revendication 1, dans lequel l'antagoniste est conjugué à des agents cytotoxiques ou cytostatiques.

10. Utilisation de l'antagoniste selon la revendication 8 pour la fabrication d'un médicament destiné à inhiber l'angio-

## EP 1 203 025 B1

génèse, la croissance de tumeur, la métastase, le psoriasis, la dégénérescence maculaire ou la resténose dans un tissu.

- 5 11. Utilisation selon la revendication 10, dans lequel ledit antagoniste est administré par voie intraveineuse, transdermique, intrasynoviale, intramusculaire, intratumorale, intraoculaire, intranasale, intrathécale, topique ou orale.
12. Utilisation selon la revendication 10, dans laquelle ledit antagoniste est administré en association avec une chimiothérapie ou en association avec une thérapie de rayonnement.
- 10 13. Utilisation selon la revendication 10, dans laquelle le tissu est enflammé et l'angiogénèse apparaît.
14. Utilisation selon la revendication 10, dans laquelle le tissu est présent chez un mammifère.
- 15 15. Utilisation selon la revendication 14, dans lequel le tissu est arthritique, oculaire, rétinale ou est un hémangiome.
16. Utilisation selon la revendication 10, dans laquelle la tumeur ou la métastase est un mélanome, un carcinome, un sarcome, un fibrosarcome, un gliome ou un astrocytome.
- 20 17. Utilisation de l'antagoniste selon la revendication 8 pour la fabrication d'un médicament destiné à détecter une angiogénèse, des tumeurs ou une invasion de tumeur dans un tissu par mise en contact dudit antagoniste avec ledit tissu.
18. Utilisation selon la revendication 17, dans laquelle ledit tissu est *ex vivo*.
- 25 19. Utilisation selon la revendication 17, dans laquelle ledit tissu est *in vivo* et ledit antagoniste est administré par voie intraveineuse, transdermique, intrasynoviale, intramusculaire, intratumorale, intraoculaire, intranasale, intrathécale, topique ou orale.
- 30 20. Utilisation selon la revendication 17, dans laquelle ledit antagoniste est conjugué à un fluorochrome, un marqueur radioactif, un métal lourd paramagnétique, un colorant de diagnostic ou une enzyme.
21. Procédé pour détecter des antagonistes de MMP-9 ou de pi intégrine comprenant :
- 35 a) la fourniture d'un antagoniste généralement reconnu ;  
b) la mesure de ladite première affinité de l'antagoniste généralement reconnu pour se lier à MMP-9 ou à une intégrine  $\beta 1$  ;  
c) la mesure d'une seconde affinité de SEQ ID NO:3 pour se lier à MMP-9 ou à ladite intégrine  $\beta 1$  ;  
d) le choix dudit antagoniste généralement reconnu comme un antagoniste de MMP-9 ou de  $\beta 1$  intégrine si ladite seconde affinité est sensiblement inférieure à ladite première affinité.
- 40 22. Procédé selon la revendication 21, dans lequel ledit antagoniste généralement reconnu est un composé non peptidique.
- 45 23. Procédé selon la revendication 22, dans lequel ledit composé non-peptidique est un petit composé organique ou un oligonucléotide.
24. Procédé selon la revendication 21, dans lequel ledit antagoniste généralement reconnu est un polypeptide, un peptide linéaire, un peptide cyclique ou un anticorps monoclonal ou polyclonal.
- 50 25. Procédé selon la revendication 21, dans lequel ladite première et ladite seconde affinité sont mesurées par un dosage par la méthode ELISA.
26. Procédé selon la revendication 21, dans lequel ladite seconde affinité est environ 3 fois inférieure à ladite première affinité.
- 55 27. Procédé selon la revendication 21, dans lequel ladite seconde affinité est environ 5 fois inférieure à ladite première affinité,

**EP 1 203 025 B1**

28. Procédé selon la revendication 21, dans lequel ladite seconde affinité est environ 10 fois inférieure à ladite première affinité.
29. Peptide consistant en la séquence aminoacide de SEQ ID NO:1 comprenant un déterminant antigénique reconnu par un antagoniste selon la revendication 5.

5

10

15

20

25

30

35

40

45

50

55




FIG. 1




FIG. 2





FIG. 3

FIG. 4






FIG. 5

FIG. 6

Co-Localization of MMP-9 and  $\beta$ 1 Integrin  
Within  
Human Melanoma Tumor Biopsy




FIG. 7






FIG. 8A

A



# FIG. 8B



**FIG. 9**

Reactivity of Hybridoma Conditioned Medium For FRIP-1 Peptide

Hybridoma Clone Name	FRIP-1 (O.D 490nm)	AAA (O.D 490nm)
FM 101	0.306 ( $\pm$ 0.041)	0.275 ( $\pm$ 0.033)
FM132	0.576 ( $\pm$ 0.022)	0.037 ( $\pm$ 0.026)
FM 155	0.481 ( $\pm$ 0.063)	0.055 ( $\pm$ 0.039)
FM 158	0.339 ( $\pm$ 0.039)	0.178 ( $\pm$ 0.066)
FM 170	0.241 ( $\pm$ 0.037)	0.201 ( $\pm$ 0.012)

FIG. 10





FIG. 11



## REFERENCES CITED IN THE DESCRIPTION

This list of references cited by the applicant is for the reader's convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.

## Patent documents cited in the description

- WO 9514714 A [0004]
- WO 9958139 A [0007]
- US 5092885 A [0010]
- US 5112946 A [0010]
- US 5192744 A [0010]
- US 5202352 A [0010]
- US 4342566 A, Theofilopolous and Dixon [0052]
- US 60143581 B [0175]
- US 60152495 B [0175]

## Non-patent literature cited in the description

- Varner, J. A. ; Brooks, P. C. ; Cheresch, D. A. *Cell Adh. Commun.*, 1995, vol. 3, 367-374 [0002] [0009]
- Blood, C. H. ; Zetter, B. R. *Biochim. Biophys. Acta*, 1990, vol. 1032, 89-118 [0002]
- Weidner, N. et al. *J. Natl. Cancer Inst.*, 1992, vol. 84, 1875-1887 [0002]
- Weidner, N. et al. *N. Engl. J. Med.*, 1991, vol. 324, 1-7 [0002]
- Brooks, P. C. et al. *J. Clin. Invest.*, 1995, vol. 96, 1815-1822 [0002]
- Brooks, P. C. et al. *Cell*, 1994, vol. 79, 1157-1164 [0002]
- Brooks, P. C. et al. *Cell*, 1996, vol. 85, 683-693 [0002]
- Brooks, P. C. et al. *Cell*, 1998, vol. 92, 391-400 [0002]
- *Circulation*, 1998, vol. 98 (17), 4166 [0003]
- *Nature Biotechnology*, August 1999, vol. 17, 768-774 [0005]
- *Cancer Research*, March 1999, vol. 59 (5), 1252-1258 [0006]
- Folkman et al. *Cancer Biology*, 1992, vol. 3, 89-96 [0010]
- Moses et al. *Science*, 1990, vol. 248, 1408-1410 [0010]
- Ingber et al. *Lab. Invest.*, 1988, vol. 59, 44-51 [0010]
- *Exp. Opin. Invest. Drugs*, 1996, vol. 5, 323-335 [0022]
- E. C. Butcher. *Cell*, 1991, vol. 67, 1033 [0026]
- T. A. Springer. *Cell*, 1994, vol. 76, 301 [0026]
- D. Cox et al. The Pharmacology of the Integrins. *Medicinal Research Rev.*, 1994, vol. 14, 195 [0026]
- Cell Adhesion Integrins as Pharmaceutical Targets. V. W. Engleman et al. *Ann. Repts. in Medicinal Chemistry*. Acad. Press, 1996, vol. 31, 191 [0026]
- Kohler ; Milstein. *Nature*, 1975, vol. 256, 495-497 [0054]
- Zola. *Monoclonal Antibodies: A Manual of Techniques*. CRC Press, Inc, 1987 [0054]
- Dulbecco et al. *Virology*, 1959, vol. 8, 396 [0059]
- Sastry et al. *Proc. Natl. Acad. Sci. USA*, 1989, vol. 86, 5728-5732 [0060]
- Huse et al. *Science*, 1989, vol. 246, 1275-1281 [0060]
- Haard, H.J. et al. *J. Biol. Chem.*, 1999, vol. 274, 18218-30 [0069]
- Winter, G. et al. *Annu. Rev. Immunol.*, 1994, vol. 12, 433-55 [0069]
- Fields, S. *Nature*, 1989, vol. 340, 245-6 [0073]
- Lowman H.B. et al. *Biochemistry*, 1991, vol. 30, 10832-8 [0075]
- Ausprunk et al. *Am. J. Pathol.*, 1975, vol. 79, 597-618 [0092]
- Ossonski et al. *Cancer Res.*, 1980, vol. 40, 2300-2309 [0092]
- D'Amato et al. *Proc. Natl. Acad. Sci.*, 1994, vol. 91, 4082-4085 [0095]
- Yan et al. *J. Clin. Invest.*, 1993, vol. 91, 986-996 [0098]
- Syrigos, K.N. *Anticancer Res.*, 1999, vol. 19, 605-13 [0144]
- Receptor Binding Techniques, *Methods in Molecular Biology*. Humana Press, 1999 [0145]
- Brooks et al. *Cell*, 1998, vol. 92, 391-400 [0145]
- Brooks et al. *Cell*, 1996, vol. 85, 683-693 [0145]
- Brooks et al. *J. Cell. Biol.*, 1993, vol. 122, 1351-1359 [0145]

